Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, October 6 University, Giza, Egypt.
Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Kasr El-Aini, Cairo, 11562, Egypt.
AAPS PharmSciTech. 2021 Feb 14;22(2):74. doi: 10.1208/s12249-021-01924-z.
The current study aimed to load terconazole (TCZ), an antifungal agent with low permeability characteristics, into highly deformable bilosomes (HBs) for augmenting its topical delivery. HBs contain edge activator in addition to the constituents of traditional bilosomes (Span 60, cholesterol, and bile salts). More elasticity is provided to the membrane of vesicles by the existence of edge activator and is expected to increase the topical permeation of TCZ. HBs were formulated using ethanol injection technique based on 2 complete factorial design to inspect the impact of various formulation variables (bile salt type and amount, edge activator type, and sonication time) on HBs characteristics (entrapment efficiency percent (EE%), particle size (PS), polydispersity index (PDI), and zeta potential (ZP)). The optimum formula (HB14) was decided based on Design-Expert software and was utilized for further explorations. HB14 exhibited EE% = 84.25 ± 0.49%, PS = 400.10 ± 1.69 nm, PDI = 0.23 ± 0.01, and ZP = - 56.20 ± 0.00 mV. HB14 showed spherical vesicles with higher deformability index (9.94 ± 1.91 g) compared to traditional bilosomal formula (3.49 ± 0.49 g). Furthermore, HB14 showed superior inhibition of Candida albicans growth relative to TCZ suspension using XTT (2,3-bis(2-methyloxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide) reduction assay. Moreover, in vivo skin deposition studies revealed superior TCZ deposition inside the skin from HB14 compared to traditional bilosomal formula and TCZ suspension. Moreover, histopathological examination in rats assured the safety of HB14 for topical use. Concisely, the obtained outcomes confirmed the pronounced efficacy of HBs for topical delivery of TCZ.
本研究旨在将具有低渗透性的抗真菌药物特比萘芬(TCZ)载入高度变形的双层囊泡(HBs)中,以增强其局部递送。HBs 除了传统双层囊泡(Span 60、胆固醇和胆汁盐)的成分外,还含有边缘活性剂。边缘活性剂的存在为囊泡的膜提供了更多的弹性,预计会增加 TCZ 的局部渗透。HBs 是通过乙醇注入技术根据 2 完整因子设计来制备的,以检查各种制剂变量(胆汁盐类型和数量、边缘活性剂类型和超声时间)对 HBs 特性(包封效率百分比(EE%)、粒径(PS)、多分散指数(PDI)和 Zeta 电位(ZP))的影响。基于 Design-Expert 软件,选择最优配方(HB14)并进行进一步探索。HB14 的 EE%=84.25±0.49%,PS=400.10±1.69nm,PDI=0.23±0.01,ZP=-56.20±0.00mV。HB14 显示出比传统双层囊泡配方(3.49±0.49g)更高的变形指数(9.94±1.91g)的球形囊泡。此外,与 TCZ 混悬剂相比,HB14 用 XTT(2,3-双(2-甲氧基-4-硝基-5-磺苯基)-2H-四唑-5-羧基苯胺)还原试验显示出对白色念珠菌生长的更好抑制作用。此外,体内皮肤沉积研究表明,与传统双层囊泡配方和 TCZ 混悬剂相比,HB14 能更好地将 TCZ 沉积在皮肤内。此外,大鼠的组织病理学检查保证了 HB14 用于局部应用的安全性。总之,研究结果证实了 HBs 对 TCZ 局部递送的显著效果。